Camurus announced the initiation of the European roll-out of weekly and monthly Buvidal® and it is now available in Finland and Sweden. Buvidal is the first long-acting medication approved in the EU for the treatment of opioid dependence in adults and adolescents from 16 years of age. Buvidal is administered as a small volume injection under the skin and is designed to deliver buprenorphine at a controlled rate over weekly and monthly dosing intervals, thereby avoiding the burdens and risks of daily medication. Buvidal has been studied in a comprehensive clinical study program, including two Phase 3 studies, where it has demonstrated effective blockade of opioid drug-liking and suppression of withdrawal, craving and patient's use of illicit opioids.